Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Typo ‘a specific area.’ If there are any biochemists out there that can explain what sets n4p apart would be very grateful for an explanation. All I see is a spiked ball that looks like one of those useless organic washing machine balls. I wonder if that’s where Nigel got the idea! Anyway, about £1.3 million left. No employees to pay. Does Nigel just have shares as payment? He got costs down to under £0.7 million. It seems most of the trials are outsourced at other peoples expense and research being funded by a grant at Queens Australia. Bit of a shoestring affair but he’s got this far. Must give him some credit for that. Typically British company
Nanotechnology In medicine has a massive future. It is all about the delivery of drugs to combat chronic disease. It is important because it can help deliver the medicine to Astor specifics area. This is vital because many medicines can be pretty toxic as can be Nanoparticles them self of which there are a few different kinds. The advantage of creating a delivery system like this is that it improves the efficacy of a medicine requiring considerably smaller doses to site specific areas with much reduced toxicity
Or side effects. Quite what N4p are trying to do or the product that they have that makes it unique enough to make it different from other nanotechnology I don’t quite understand. I’m not a biochemist . But here we are with a patented product that can potentially greatly improve the chances of people recovering from horrible chronic illnesses, cancers, IBS and improve the immunity boosting vaccine injections and possible orally which would be another massive leap forward not to mention facilitating the transportation and storage of medicines. The stakes are enormous monetarily but also for helping medicines become more accessible, cost efficient and effective. Who said it would be easy ? You have to be in it to win it . It may not turn out to be N4p but there again there is a realistic chance it very much could be.
Nigel is living it up in some hot country spending shareholders money! Bloke is a joke!
The main thing that annoys me is Nigel said this would be a news rich year.
143 days since the last siRNA update .... Over a 3rd of a year !!!! WTF
You can have all the patents in the world but if you've got no product, don't mean S@£%!!!!
I think it is safe to say we are going to be hanging around these low numbers for some time if we are ever to see another rise.
i'm personally going to try to bring my average as low as i can whilst the share is at this level. This prove pointless or poignant, time will tell.
The joys of investing.
Rich tea by the looks of it 🤣 ....
As we all know there’s a massive risk with investing but this share has took the biscuit
Not sure which needle your using ??? Most needles go up , this certainly ain't doing that ....
Down ,Down ,Down .....
Certainly nice to see the needle moving
Got volume today which is always wecome ...means liquiduty flowing
No doubt there will be a fund raise.
Just a huge gamble here now.
Been holding years with nothing but loses.
NOTE
I've said it before ...chatboards do more harm to sp then it really is ,everyone is a BOD on them ....all comments are anticipation rather than facts ,
The cold facts are that N4P have 6 months to deliver commercialisation or another fund raise will be due
No m'ment for 5 hours ....only move now is up imho
Sorry you can't release any news in an interim results. What did you expect.
At last an update.
Certainly not bad news although the sp has responded in such a way. I would imagine the guys looking for a quick buck have sold up and might look back at us when some more concrete news is in place.
The potential is certainly underlined here which is great to see. All we can ask is that N4P offer us positive news. We have no input how the market interprets the news.
From my perspective despite there being no big positive news there is also nothing negative which i had personally feared.
being on track and business as usual is good news i would say. i just hope their marketing team see's the sense in reiterating all this positive news to the public to bring in new investors.
time to top up
Progressing, conserving cash and sounding like they are definitely going to create their own product to get into clinic faster.
A boring update but thankfully no bad news.
Wully, in my eyes I was just glad there was no negative news. So actually for me was good rns…lol.
Nice summary Brighty
Some very upbeat news for N4P investors today. Highlights below...
* Encouraging results from our existing data package has prompted further exploratory conversations with potential collaborators = that is very good news
* Nuvec® loaded with an adenovirus viral vector can increase performance of the viral vector by 20-30 fold = that is brilliant news
* Continued to make excellent progress in the period with our pre-clinical work = that is very good news
* Cash position remains strong which at 30 June 2023 was £1,289,769 = that is very good news
* Second Nuvec® patent granted = that is very good news
* Nuvec comparable to Roche's Venetoclax and AZ's Gefitinib / similar to commercially available small molecules = that is excellent news
* The market for manufacturing viral vectors, in terms of revenue, was estimated to be worth $5.5 billion in 2023 and is poised to reach $12.8 billion by 2028, growing at a CAGR of 18.2% from 2023 to 2028 = that is excellent news
* Viral Vectors remain the "go to" delivery vehicle for use in gene therapy. As a result, companies operating in this space are increasingly looking at non-viral delivery systems that can be used to replace viral vectors = that is excellent news.
* Nuvec® has the potential to replace viral vectors as a delivery vehicle but also the Company has shown that Nuvec® can be combined with the viral vector to significantly improve its efficiency. i.e. Nuvec® can possibly address this area = that is excellent news.
Summary: Many many positives announced today and looks like more collaborator news also coming too....
Good luck, Brighty
1.20
I do not think it was a bad interims update.
There would not be anything price sensitive to mention otherwise it would have been rns'ed before today.
Nothing in that RNS that we already didn't no !! Big RED day for n4p !!!